Phase 3 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate cancer (a specific type called adenocarcinoma), confirmed through a tissue sample analysis
- People whose cancer is considered low risk, meaning the cancer is contained within or close to the prostate, has a low grade group score (grade group 1), and a PSA level below 10 ng/ml
- People whose cancer is considered favorable intermediate risk, meaning only one of the following applies: cancer has grown to a certain stage (T2c), a slightly higher grade group score (grade group 2), or a PSA level between 10 and 20 ng/ml — and no more than 50% of the tissue samples taken during biopsy contain cancer
- People whose prostate is smaller than 60cc in size, as measured by ultrasound, CT scan, or MRI
- People who are able to undergo an MRI scan
- People who are willing and able to give written consent to participate
Who may not be able to join:
- People whose cancer has spread to the lymph nodes or other parts of the body
- People who have previously had radiotherapy to the pelvic area
- People who have previously had prostate surgery, including procedures to remove the prostate, a procedure called transurethral resection of the prostate (TURP), or a treatment called HIFU
- People who are currently using hormone therapy to reduce testosterone (known as androgen deprivation therapy) — note that a separate type of medication called 5-alpha-reductase inhibitors is permitted
- People who have significant urinary problems before the trial, based on a symptom score above 15 on a standard questionnaire (confirm with trial site)
- People who have a medical condition that would make standard prostate radiotherapy unsafe, such as certain connective tissue diseases or inflammatory bowel disease
- People who have serious health conditions that would make it unsafe to undergo a general anaesthetic
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Andrew Loblaw, MD, Sunnybrook Health Sciences Centre
Phone: 416-480-6100
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Acute Toxicities
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.